CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.
|Strength||20 mg, 40 mg & 60 mg|
|Indication||Renal Cell Carcinoma|
|Funding Request||For the treatment of patients with advanced renal cell carcinoma (RCC) who have received prior therapy.|
|Pre Noc Submission||No|
|NOC Date||September 14, 2018|
|Manufacturer||Ipsen Biopharmaceuticals Canada Inc.|
|Sponsor||Ipsen Biopharmaceuticals Canada Inc.|
|Submission Date||September 17, 2018|
|Submission Deemed Complete||October 2, 2018|
|Stakeholder Input Deadline ‡||October 2, 2018|
|Check-point meeting||November 6, 2018|
|pERC Meeting||January 17, 2019|
|Initial Recommendation Issued||January 31, 2019|
|Feedback Deadline ‡||February 14, 2019|
|Final Recommendation Issued||February 20, 2019|
|Notification to Implement Issued||March 7, 2019|
|Therapeutic Area||Renal Cell Carcinoma (RCC)|
|Recommendation Type||Reimburse with clinical criteria and/or conditions|
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.